Hemostatic Nanoparticles Improve Survival Following Blunt Trauma Even after 1 Week Incubation at 50°C.
According to the CDC, the leading cause of death for both men and women between the ages of 5 and 44 is traumatic injury. Blood loss is the primary cause of death at acute time points post trauma. Early intervention is critical to save lives, and yet there are no treatments to stop internal bleeding that can be deployed in the field. In this work, we developed hemostatic nanoparticles that are stable at high temperatures (50 °C for 7 days) and are still effective at stopping bleeding and improving survival over the one hour time period in a rat liver injury model. These particles are exceptionally simple: PLA-based nanospheres functionalized with PEG terminated with variants of the RGD motif. This simple system can be stored at temperatures up to 50°C and maintain size, shape, and efficacy. The particles lead to a reduction in bleeding and increased acute survival with significance compared to both control particles and saline. Overall, these hemostatic nanoparticles offer an important step towards an immediate intervention in the field to stop bleeding and improve survival.
Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106.
Margaret
M
Lashof-Sullivan
Macromolecular Science and Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106.
Mark
M
Holland
Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106.
Rebecca
R
Groynom
Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106.
Donald
D
Campbell
Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, 44106.
Andrew
A
Shoffstall
Chemical, Biochemical, and Environmental Engineering, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD, 21250.
Erin
E
Lavik
artificial fibrinogen; artificial platelet; bleeding; blunt trauma; fibrinogen; hemostasis; liver injury; synthetic fibrinogen; synthetic platelet
Nanoscale. 2013 Nov 21;5(22):10719-28
24088870
J Trauma. 2006 Jun;60(6 Suppl):S3-11
16763478
Bioconjug Chem. 2009 Oct 21;20(10):1958-65
19788180
J Trauma. 2005 Jul;59(1):8-15; discussion 15-8
16096533
Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10293-8
24982180
Curr Opin Crit Care. 2004 Dec;10(6):520-8
15616396
Ann Emerg Med. 1989 Feb;18(2):173-6
2916782
Shock. 2013 Feb;39(2):121-6
23222525
J Control Release. 2012 Aug 20;162(1):37-44
22705460
Am J Health Syst Pharm. 2008 Sep 1;65(17):1616-23
18714107
Macromol Biosci. 2005 Jul 14;5(7):569-97
15997437
Nat Mater. 2014 Dec;13(12):1108-14
25194701
Am Surg. 2008 Dec;74(12 ):1159-65
19097529
Transfusion. 2013 Jan;53 Suppl 1:100S-106S
23301961
J Trauma. 2000 Aug;49(2):246-50
10963535
Biomacromolecules. 2012 Nov 12;13(11):3850-7
22998772
Biomacromolecules. 2013 Aug 12;14(8):2790-7
23841817
Transfusion. 2013 Jan;53 Suppl 1:96S-99S
23301980
Nat Med. 1999 Jan;5(1):107-11
9883848
Mil Med. 2008 Nov;173(11):1057-9
19055178
Resuscitation. 2006 Jul;70(1):133-44
16757085
J Trauma. 2003 May;54(5 Suppl):S13-9
12768096
Am Surg. 2011 Aug;77(8):1043-9
21944521
J Clin Invest. 1992 Feb;89(2):546-55
1737845
Am J Public Health. 2000 Apr;90(4):523-6
10754963
Nano Lett. 2005 Feb;5(2):315-9
15794618
J Trauma Acute Care Surg. 2012 Dec;73(6 Suppl 5):S431-7
23192066
Sci Transl Med. 2009 Dec 16;1(11):11ra22
20371456
Mil Med. 2004 Dec;169(12 Suppl):8-10, 4
15651433
Am Surg. 2005 Sep;71(9):776-80
16468517
J Am Coll Surg. 1998 May;186(5):528-33
9583692
J Am Chem Soc. 2002 Feb 13;124(6):914-5
11829593